Imatinib Mesylate from Japan
Imatinib mesylate is a tyrosine kinase inhibitor used primarily as an anticancer drug for treating chronic myeloid leukemia. This aromatic heterocyclic compound with nitrogen hetero-atoms falls under HTS 2933.99.75.00 as it is classified as a drug containing a modified aromatic nitrogen heterocyclic structure.
Duty Rate — Japan → United States
12.5%
Rate breakdown
9903.05.4912.5%Section 301 (forced labor) — Japan (col1 rate < 12.5 percent): MFN < 12.5% → total duty capped at 12.5%
Import Tips
• Obtain FDA approval and Drug Master File (DMF) prior to import as it's a pharmaceutical substance
• Ensure Certificate of Analysis (CoA) verifies purity >99% and compliance with USP standards
• Avoid misclassification as a research chemical; declare as bulk drug substance for medicinal use